CL-WV Holdings LLC, an advanced materials development company, has named Charles McCullough, III as its fourth board member, it was reported yesterday.
McCullough is an experienced attorney with an extensive background working with policy makers at the highest levels. He led the Intelligence Community Inspectors General Forum, which included all 17 Inspectors General that make up the Intelligence Community. His responsibilities included government auditing, compliance, and oversight in many roles throughout his extensive career within the US Government.
McCullough is a partner at Compass Rose Legal Group and a former Presidentially-appointed and Senate confirmed inspector general. Specifically, he was the inspector general of the Intelligence Community. In this role, he reported directly to then-director of National Intelligence, the Honourable James R Clapper, and oversaw intelligence officers responsible for audits, inspections, investigations. Furthermore, he was responsible for inquiries involving the Office of the Director of National Intelligence and the entire Intelligence Community. Prior to his Presidential appointment, he held positions with the National Security Agency, the US Department of the Treasury, and the Federal Bureau of Investigations.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'